Duality Advisers’s AtriCure ATRC Stock Holding History

Duality Advisers’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-34,781	Closed	-$1.42M	–	532
2022 Q2	$1.42M	Buy	+34,781	New	+$1.65M	0.14%	275
2021 Q4	–	Sell	-9,240	Closed	-$643K	–	493
2021 Q3	$643K	Buy	+9,240	New	+$711K	0.05%	411
2020 Q4	–	Sell	-29,500	Closed	-$1.18M	–	550
2020 Q3	$1.18M	Buy	+29,500	New	+$1.25M	0.08%	337

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Duality Advisers's ATRC Position: Q3 2022 in Review

Duality Advisers sold out of AtriCure (ATRC) in Q3 2022, closing a stake of 34,781 shares — an estimated $1.42M sold.

Duality Advisers first reported a position in ATRC in Q3 2020 and held it in 3 quarters. The position peaked at $1.42M in Q2 2022. 214 funds tracked by Wall St. Rank hold ATRC as of Q3 2022.

Duality Advisers reported no remaining AtriCure position as of Q3 2022 after selling out during the quarter.
Duality Advisers sold 34,781 AtriCure shares in Q3 2022, an estimated $1.42M.
Duality Advisers first reported a position in AtriCure in Q3 2020 and held it in 3 quarters.
Duality Advisers's AtriCure position peaked at $1.42M in Q2 2022.
214 funds tracked by Wall St. Rank held AtriCure as of Q3 2022.

Based on Duality Advisers's 13F filing for Q3 2022, filed 3 Nov 2022.